Naked ambition

Proof-of-concept data from miRagen Therapeutics Inc. show systemic delivery of its lead candidate can shrink lesions in cutaneous T cell lymphoma, and that its oligonucleotide platform can achieve broad distribution and a long half-life without the addition of a conjugate or vehicle.

On Oct. 13, miRagen reported interim data from a Phase I trial of MRG-106 to treat mycosis fungoides-type cutaneous T cell lymphoma (CTCL). All but one of the 23 patients treated showed improvement in total skin disease measured as the change from baseline in modified Severity Weighted Assessment Tool (mSWAT) score. mSWAT assesses skin disease over the entire body. ...